text stringlengths 1 654k |
|---|
OD SVR12 (GT1a) |
52/53 (98%) |
24/27 (89%) |
OD SVR12 (GT1b) |
24/24 (100%) |
14/14 (100%) |
OD SVR12 (IL28B non-CC) |
54/55 (98%) |
36/39 (92%) |
*Did not follow up (2 treatment-naïve patients and 1 null responder) or have not yet reached PTW12 (3 null responders) |
Additional data presented in the abstract represent all 8- and 12-week arms (n=448) of this 14-arm study (571 patients enrolled: 438 treatment-naive and 133 prior null responders). SVR12 rates for other 8- and 12-week regimens ranged from 89-92 percent. Complete SVR12 data for 8- and 12-week arms will be presented at the Liver Meeting. |
Four of 448 patients (one percent) in the 8- and 12-week arms discontinued due to adverse events. Of five serious AEs (1 percent), 1 (arthralgia or joint pain) was possibly study drug-related. In the trial, the most common adverse events were fatigue (28 and 27 percent) and headache (28 and 31 percent) for treatment naïve and null responders respectively. |
Abbott Data at AASLD |
In addition to Aviator, there are four poster presentations on Abbott's investigational medicines for the treatment of HCV: |
Tami Pilot-Matias et al.; Sunday, November 11 (8:00 a.m.-5:30 p.m. ET) |
"Characterization of Resistant Variants in NS3 and NS5B Detected in Subjects Treated with ABT-450/r, Ribavirin, and Either ABT-072 or ABT-333 in the Pilot and Co-Pilot Studies Who Experienced Virologic Breakthrough or Relapse" |
Preethi Krishnan et al.; Tuesday, November 13 (8:00 a.m.-12:00 p.m. ET) |
"Antiviral Activity and Resistance Profiles for ABT-267, a Novel HCV NS5A Inhibitor, In Vitro and During 3-Day Monotherapy in HCV Genotype-1 (GT1)-Infected Treatment-Naive Subjects" |
Lane Kirbach et al.; Tuesday, November 13 (8:00 a.m.-12:00 p.m. ET) |
"Evaluation of Patient Preferences for Treatment Outcomes in Hepatitis C Virus (HCV)" |
Amit Khatri et al.; Sunday, November 11 (8:00 a.m.-5:30 p.m. ET) |
"Pharmacokinetics and Safety of Co-administered ABT-450 plus Ritonavir (ABT-450/r), ABT-267 and ABT-333 as a Single Dose in Subjects with Normal Hepatic Function and in Subjects with Mild, Moderate and Severe Hepatic Impairment" |
About the Hepatitis C Virus |
Hepatitis C is a liver disease affecting as many as 170 million people worldwide. The virus is primarily spread through direct contact with the blood of an infected person. HCV increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death; and liver disease associated with HCV infection is growing rapidly. |
About Abbott's HCV Development Programs |
Abbott's HCV portfolio includes investigational medicines with three different mechanisms of action, including protease (ABT-450/r), polymerase (ABT-333) and NS5A (ABT-267) inhibitors, currently being studied in clinical trials. ABT-450 is being developed with low dose ritonavir which enhances the pharmacokinetic properties of ABT-450. The use of ritonavir 100 mg with ABT-450 for the treatment of HCV is investigational. ABT-450 was discovered during the course of a collaboration between Abbott and Enanta Pharmaceuticals for HCV protease inhibitors and regimens that include protease inhibitors. |
ABT-450 is being developed by Abbott for use in combination with Abbott's other investigational medicines for the treatment of HCV. Abbott is well-positioned to explore combinations and co-formulations of these medicines. |
Ritonavir Use in Treatment of HIV |
Ritonavir is in a class of medicines called the HIV protease inhibitors. Ritonavir is used in combination with other anti-HIV medicines to treat people with human immunodeficiency virus (HIV) infection. Ritonavir is for adults and for children greater than 1 month in age and older. |
Ritonavir does not cure HIV infection or AIDS and does not reduce the risk of passing HIV to others. People taking ritonavir may still get opportunistic infections or other conditions that happen with HIV infection. Some of these conditions are pneumonia, herpes virus infections, and Mycobacterium avium complex (MAC) infections. |
Ritonavir Safety in Treatment of HIV |
Patients should not take ritonavir with certain medicines, as these can cause serious or life-threatening problems such as irregular heartbeat, breathing difficulties, or excessive sleepiness. Patients should not take ritonavir if they have had a serious allergic reaction to any of its ingredients. Some patients taking ritonavir may develop liver and pancreas problems, which can cause death. |
Patients may develop large increases in triglycerides and cholesterol, diabetes, high blood sugar, changes in body fat, increased bleeding in people with hemophilia, allergic reactions, and/or changes in heart rhythm. Patients may develop signs and symptoms of infections that they already have after starting anti-HIV medicines. |
For more information, please see the Important Safety Information and full Prescribing Information for ritonavir. |
About Abbott |
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries. |
Abbott's news releases and other information are available on the company's website at www.abbott.com. |
SOURCE Abbott |
Suggested Articles |
The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday. |
On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits. |
Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction. |
Set in stone |
Though the vibe is 100% Jerusalem, Lara incorporates international culinary influences on its meaty menu. |
By SHIRA TEGER |
August 13, 2010 15:51 |
3 minute read. |
The Lara Jerusalem Bistro |
bistro311. (photo credit: Courtesy) |
Sometimes when you enter a restaurant, you feel you’ve been transported elsewhere, whether it’s to a little cafe in Italy or a busy Japanese sushi bar. But other times, a local restaurant feels local. The new Lara bistro in downtown Jerusalem sticks to its roots with an authentic Jerusalem vibe, with stone floors, arched ceilings, a large Jerusalem mural and street lamps illuminating the interior. |
Seating options abound, from outdoor tables on the Shimon Ben- Shetah pedestrian street to indoor tables to bar seating to kitchen-window stools. It’s an upper-class joint, with cloth napkins and leather-bound menus, even if it is a bit noisy. |
Chef Lior Haftzadi (of Arcadia, Canela and Ristorante de Vitorio fame) wanted my dining companion and me to get a good understanding of the menu the restaurant has to offer, so after we provided a little guidance as to our likes and dislikes, we were brought a parade of tastes. The menu offers a wide variety of culinary styles, taking from Israeli, Italian, French, Asian and Middle Eastern kitchens. However, Lara is very heavy on meat, with only a few vegetarian options. |
Our Asian trip involved very fresh sea bass sashimi with an exceptional lentil salad. The Italian exploration included bruschetta with a combo of medium-rare roast beef and a tender, almost creamy pickled sirloin (NIS 38) along with a surprisingly flavorful mushroom risotto that seemed to involve evolving layers of taste (NIS 42). Mediterranean and Middle Eastern dishes encompassed an heirloom eggplant dish for vegetarian diners, which my dining partner termed “not boring.” There were also tender veal tonsils with Swiss chard and arisa (NIS 48) and even more tender veal brain with a smoked paprika coating (NIS 38). Wait, don’t stop reading: Those were the only offbeat things we tried. |
We had two types of kebab: fish and meat (NIS 44 and NIS 38, respectively). The fish was very heavy on cilantro, but it came with a fantastic tabbouleh salad with a brilliant addition of dried cranberries. |
The meat had fun pine nuts and tasty green onion in it, but it was too salty. It came with a very light and refreshing potato salad. And if that weren’t all carnivorous enough, we also tried the beef fillet (NIS 118) and lamb chops. The fillet came with a thin red wine sauce, delicious asparagus and light and fluffy mashed potatoes. The meat itself was fine, though nothing too juicy to write home about. The lamb had a strong hint of black pepper and a strangely absent hint of lamb flavor. |
The presentation of the dishes throughout was attractive and almost homestyle: There was garnish, but Lara didn’t go overboard with it. The service was attentive and friendly, and even informative. |
For dessert, we delighted in a pineapple carpaccio with coconut sorbet, and tapioca with melon sauce, topped with candied nuts and fresh fruit (NIS 32). We’d hoped to taste the chocolate gnocchi listed on the menu, but they didn’t have any. |
Lara is still new, so chances are the menu will undergo changes with time (in fact, the reason the prices are missing for some of the aforementioned dishes is because they aren’t yet listed on the menu). The atmosphere is certainly pleasant, and the décor is special. |
As the restaurant joined a row of mostly established eateries on Ben- Shetah, it’s good to have something to set it apart. Haftzadi knows what he’s doing in the kitchen, although it seems that sometimes he goes overboard with cilantro and salt. Still, Lara is a good restaurant, even if it isn’t mind-blowing. And with such a varied menu, it’s a great option for when one person wants Italian and the other wants French. |
Lara Jerusalem Bistro, Rehov Shimon Ben-Shetah 3, Jerusalem, (02) 537-0701. |
Open 6 p.m. to midnight. Kosher. |
Related Content |
Sarah Silverman |
August 26, 2014 |
Jewish women take home gold at 2014 Emmys |
By JTA |
Cookie Settings |
| FREE SHIPPING FOR ORDERS OVER $80 |
Allegra Fairtrade Coffee 10 Nespresso® Compatible Pods |
Allegra Fairtrade Coffee 10 Nespresso® Compatible Pods |
Brand:Dingo Republic |
Product Code:00501003 |
EAN134_au |
Availability:In Stock |
Price: AU$5.90 AU$5.90 Ex Tax: AU$5.90 |
Qty: - OR - Add to Wish List Add to Compare |
Allegra Fairtrade (12/12) |
The secret of the Allegra Blend is the relaxed complexity of the Brazilian and Indian Fairtrade coffees. An exceptional intensity exhibits a bold, flavoursome and full-body character. |
Allegra works well as a classic Italian style espresso or with milk as a Capuccino. A perfect start to your day! |
In our continuous effort to provide responsible coffee options, Allegra, Indira and Colombiana are now all Fairtrade Certified! |
Please note that during the transition to Fairtrade coffees, Allegra, Indira and Colombiana will be housed in plain black packaging. We expect the transition to last 3 - 4 weeks, after which time our colourful and much-loved Dingo Republic packaging will be back! |
Roasted and Packed in Australia from Premium imported Fairtrade Coffee in 100% Nespresso® Compatible hermetically sealed coloured capsules. |
Intensity: 12 |
Size of Cup: 40m-110ml |
Capsules Per Box: 10 Capsules (hermetically sealed, black capsules) |
Coffee per Capsule: 5.6 Grams |
100% Compatible with: Nespresso®* System |
Origin: Roasted and Packaged in Australia from imported Fairtrade Coffees |
Buy bulk and save more |
Hello Guest | Register | Forgot password |
Bertie Leahong |
First name: |
Bertie |
Family name: |
Leahong |
Nationality: |
Jamaica |
Gender: |
M |
Date of birth: |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.